Skip to content

Study · Randomized controlled trial · n = 164 · 2009

4 results

Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study.

Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K

Reproductive biomedicine online1 Oct 2009Cited by 35 (Europe PMC)

PMID19909586 (opens in a new tab)DOI10.1016/j.rbmo.2009.04.001 (opens in a new tab)PepBankPUB-19909586
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ICSI patients, additional luteal-phase leuprolide significantly increased implantation rates versus standard support alone.

    In plain wordsIn ICSI patients, additional leuprolide increased implantation rates versus standard support alone.

    Peptide
    Leuprolide
    Outcome
    IncreaseImplantation rate
    Study

    n = 164

    Comparator
    Standard luteal support without additional leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg single dose · subcutaneousAs given in this study (human).

    Measurements

    P
    < 0.05
    between groups

    Source sentences

    Summary
    Although the number of embryos transferred and the grade of the embryos were similar in the two groups, the patients in the luteal-phase agonist group had significantly higher rates of implantation and clinical pregnancy rates ( P < 0.05).
    4 context sentences
    Summary · context
    The study population consisted of 164 patients who underwent intracytoplasmic sperm injection (ICSI) after ovulation induction by gonadotrophins and GnRH antagonist for the prevention of a premature LH surge.
    Summary · context
    For luteal-phase support, all the cases received intravaginal 600 mg micronized progesterone.
    Summary · context
    In this prospective study, patients were randomly assigned to two groups.
    Summary · context
    In one group, patients received an additional single dose of GnRH agonist (0.5 mg leuprolide acetate) subcutaneously on day 6 after ICSI, whereas the patients in the other group did not.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In ICSI patients, additional luteal-phase leuprolide significantly increased clinical pregnancy rates versus standard support alone.

    In plain wordsIn ICSI patients, additional leuprolide increased clinical pregnancy rates versus standard support alone.

    Peptide
    Leuprolide
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 164

    Comparator
    Standard luteal support without additional leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg single dose · subcutaneousAs given in this study (human).

    Measurements

    P
    < 0.05
    between groups

    Source sentences

    Summary
    Although the number of embryos transferred and the grade of the embryos were similar in the two groups, the patients in the luteal-phase agonist group had significantly higher rates of implantation and clinical pregnancy rates ( P < 0.05).
    4 context sentences
    Summary · context
    The study population consisted of 164 patients who underwent intracytoplasmic sperm injection (ICSI) after ovulation induction by gonadotrophins and GnRH antagonist for the prevention of a premature LH surge.
    Summary · context
    For luteal-phase support, all the cases received intravaginal 600 mg micronized progesterone.
    Summary · context
    In this prospective study, patients were randomly assigned to two groups.
    Summary · context
    In one group, patients received an additional single dose of GnRH agonist (0.5 mg leuprolide acetate) subcutaneously on day 6 after ICSI, whereas the patients in the other group did not.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In ICSI patients, multiple pregnancy rates differed significantly between additional luteal-phase leuprolide and standard support alone, with direction unstated.

    In plain wordsIn ICSI patients, multiple pregnancy rates differed between additional leuprolide and standard support alone. The abstract does not state the direction.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedMultiple pregnancy rate
    Study

    n = 164

    Comparator
    Standard luteal support without additional leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg single dose · subcutaneousAs given in this study (human).

    Measurements

    P
    < 0.05
    between groups

    Source sentences

    Summary
    When the two groups were compared, there were also statistically significant differences in multiple pregnancy and live birth rates ( P < 0.05).
    4 context sentences
    Summary · context
    The study population consisted of 164 patients who underwent intracytoplasmic sperm injection (ICSI) after ovulation induction by gonadotrophins and GnRH antagonist for the prevention of a premature LH surge.
    Summary · context
    For luteal-phase support, all the cases received intravaginal 600 mg micronized progesterone.
    Summary · context
    In this prospective study, patients were randomly assigned to two groups.
    Summary · context
    In one group, patients received an additional single dose of GnRH agonist (0.5 mg leuprolide acetate) subcutaneously on day 6 after ICSI, whereas the patients in the other group did not.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In ICSI patients, live birth rates differed significantly between additional luteal-phase leuprolide and standard support alone, with direction unstated.

    In plain wordsIn ICSI patients, live birth rates differed between additional leuprolide and standard support alone. The abstract does not state the direction.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedLive birth rate
    Study

    n = 164

    Comparator
    Standard luteal support without additional leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg single dose · subcutaneousAs given in this study (human).

    Measurements

    P
    < 0.05
    between groups

    Source sentences

    Summary
    When the two groups were compared, there were also statistically significant differences in multiple pregnancy and live birth rates ( P < 0.05).
    4 context sentences
    Summary · context
    The study population consisted of 164 patients who underwent intracytoplasmic sperm injection (ICSI) after ovulation induction by gonadotrophins and GnRH antagonist for the prevention of a premature LH surge.
    Summary · context
    For luteal-phase support, all the cases received intravaginal 600 mg micronized progesterone.
    Summary · context
    In this prospective study, patients were randomly assigned to two groups.
    Summary · context
    In one group, patients received an additional single dose of GnRH agonist (0.5 mg leuprolide acetate) subcutaneously on day 6 after ICSI, whereas the patients in the other group did not.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.